Patent · US Active

RasGAP derived peptide for selectively killing cancer cells

US8110544B2 · kind B2 · utility

0Cited by

2References

55Claims

0Family size

Assignee

Universite de Lausanne · CH

Inventors

Christian Widmann · Lausanne, CH
Jiang Yang · Lausanne, CH
David Michod · Lausanne, CH

Key dates

Filing date	Jun 30, 2004
Grant date	Feb 7, 2012
Priority date	—
Expiry date	Jun 11, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a peptide consisting in the N2 sequence of the RasGAP protein, a fragment thereof, or a variant thereof which enhances the ability of a drug to selectively kill cells. Furthermore, it relates to a pharmaceutical composition comprising as an active substance a pharmaceutically effective amount of the peptide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.